ArticleInternational journal of hematology2026
Cardiovascular events in aging Japanese people with hemophilia: a 3-year interim analysis of the ADVANCE Japan cohort.
Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
As life expectancy increases in people with hemophilia (PWH), cardiovascular disease (CVD) has emerged as an important comorbidity. However, prospective data on CVD occurrence and its clinical management remain limited. We performed a prespecified 3-year interim analysis of ADVANCE Japan, an ongoing 10-year multicenter prospective cohort study of PWH aged ≥ 40 years, to describe CVD occurrence, clinical management, bleeding outcomes, and associated changes in hemostatic treatment. We also explored factors associated with CVD occurrence using Cox proportional hazards models. Among 588 participants, 24 developed CVD, yielding 26 events over 3 years (cumulative incidence, 4.1%). Ischemic heart disease was the most frequent event. Exploratory analyses suggested that older age, dyslipidemia, and current smoking were associated with CVD occurrence, although estimates were imprecise because of the limited number of events. Antiplatelet or anticoagulant therapy was administered to selected patients, and hemostatic management was frequently modified following CVD events. One major bleeding event was observed among patients receiving antithrombotic therapy. This prespecified interim analysis provides prospective real-world data on the occurrence and clinical management of CVD in aging Japanese PWH. Risk factor analyses should be considered exploratory, and continued follow-up is required to define long-term cardiovascular risk and outcomes in this population.
Indexed as
Identifiers
42859341What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.